UCB SA (UCBJY)
| Market Cap | 59.30B +98.3% |
| Revenue (ttm) | 9.09B +25.8% |
| Net Income | 1.83B +46.3% |
| EPS | 9.43 +46.5% |
| Shares Out | n/a |
| PE Ratio | 32.42 |
| Forward PE | 24.48 |
| Dividend | 0.48 (0.32%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 3,256 |
| Average Volume | 50,972 |
| Open | 150.59 |
| Previous Close | 153.40 |
| Day's Range | 149.48 - 152.49 |
| 52-Week Range | 76.52 - 168.76 |
| Beta | 0.23 |
| RSI | 45.27 |
| Earnings Date | Jul 30, 2026 |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for... [Read more]
Financial Performance
In 2025, UCB SA's revenue was 7.74 billion, an increase of 25.83% compared to the previous year's 6.15 billion. Earnings were 1.56 billion, an increase of 46.29%.
Financial numbers in EUR Financial StatementsNews
Belgium's UCB in autoimmune drug deal with Antengene
Belgian drugmaker UCB has entered into an agreement to licence Antengene's experimental autoimmune disease therapy ATG-201 and associated technology, paying $60 million up front and over $1.1 billio...
U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
Approved indication: KYGEVVI® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with...